MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 


Receive this page by email each issue: [Sign up for eTOCs]

Cover Image
Other Issues:
Previous Next
Contents: June 1 2006, Volume 6, Issue 3   [Index by Author] 
      Down Viewpoints
      Down Reviews
      Down Reflections
      Down Nascent Transcripts
      Down Beyond the Bench
      Down Net Results
      Down Outliers
Find articles in this issue containing these words:
[Search ALL Issues]


Table of Contents (PDF) | Editorial Board (PDF) | Front Matter (PDF) | Back Matter (PDF) | Advertising (PDF)
To see an article, click its [Full Text] or [PDF] link. To review many summaries, check the boxes to the left of the titles you want, and click the 'Get All Checked Summary(s)' button. To see one summary at a time, click its [Summary] link.

Viewpoints:Back

Dispatches from the Frontlines of Research - edited by John W. Nelson

Izabela Podgorski and Bonnie F. Sloane
Loss of Caspase-8 in Tumor Cells: Mechanism to Overcome Integrin-Mediated Death?
Mol. Interv. 2006 6: 132-136. [Summary] [Full Text] [PDF]  

Thomas E. Willnow and Olav M. Andersen
Pin-pointing APP Processing
Mol. Interv. 2006 6: 137-139. [Summary] [Full Text] [PDF]  

R E V I E W S:Back

Michael Dean
CANCER STEM CELLS: Redefining the Paradigm of Cancer Treatment Strategies
Mol. Interv. 2006 6: 140-148. [Summary] [Full Text] [PDF]  

Cancer cells divide rapidly and are immortal, as are embryonic stem cells. Indeed, the term "cancer stem cells" has arisen to describe self-renewing cells within a tumor. The cancer stem cells appear to be a minority of cells in a tumor capable of immortal growth and allowing tumor transplantation. Many researchers now suspect all cancers are composed of a mixture of renewing stem cells and "committed" cells that continue to proliferate but have a limited life span. The implications of this concept are important for basic science as well as cancer therapy, because cancers that are refractory to chemotherapy, typically comprised of cells that express drug transporters and DNA repair systems, could represent the survival of cancer stem cells.

Christian C. Felder, Amy K. Dickason-Chesterfield, and Steven A. Moore
Cannabinoids Biology: The Search for New Therapeutic Targets
Mol. Interv. 2006 6: 149-161. [Summary] [Full Text] [PDF]  

Anandamide is an endogenous lipid agonist of cannabinoid CB1 and CB2 receptors, and drugs that mimic or block anandamide agonism are currently being sought to treat numerous ailments, including pain, anxiety-related disorders, and obesity. But the unique routes of anandamide synthesis, turnover, and reuptake may offer avenues for therapeutic intervention other than modulation of cannabinoid receptor activation per se. Anandamide is generated from N-arachidonoyl phosphatidylethanol-amine within the plasma membrane, and the cellular activities that must be engaged for its arrival at the cannabinoid receptor, as well as its hydrolysis by enzymes that appear primarily in the cytoplasm, continue to be unraveled by investigators. As the mechanisms for anandamide transport become elucidated, novel targets within the endocannabinoid signaling system may be identified for drug design.

Emily M. Jutkiewicz
The Antidepressant -like Effects of Delta-Opioid Receptor Agonists
Mol. Interv. 2006 6: 162-169. [Summary] [Full Text] [PDF]  

Initially, it was expected that agonists of the delta-opioid receptor (DOR) would have antinociceptive properties similar to those of other opioids, without negative side effects such as respiratory depression, physical dependence, and abuse potential. Indeed, nonpeptidic delta-opioid agonists, which have greatly advanced our appreciation of DOR function, are devoid of undesirable effects, such as respiratory depression, reinforcing effects, and withdrawal symptoms, but they also have minimal pain-relieving qualities. Most intriguing is the finding that DOR agonists may have antidepressant-like effects, but the development of these compounds as antidepressants is hindered by their apparent convulsive activity. Although polypharmacy may circumvent the convulsive properties of delta-opioid agonists, the development of new nonpeptidic delta-opioid antidepressants without side effects is an ongoing goal.

D E P A R T M E N T S:Back

Reflections:Back

Science in the cultural context

Stanley Scheindlin
The Fight Against Tuberculosis
Mol. Interv. 2006 6: 124-130. [Full Text] [PDF]  

Nascent Transcripts:Back

Emerging concepts from the recent literature
Mol. Interv. 2006 6: 131. [Full Text] [PDF]  

Beyond the Bench:Back

Representations of pharmacology and science in the media

Dan Collinge
The Dark Side of the Periodic Table
Mol. Interv. 2006 6: 170-171. [Full Text] [PDF]  

Net Results:Back

Sites of interest on the World Wide Web

Sites of interest on the World Wide Web—edited by David Roman
Mol. Interv. 2006 6: 172. [Full Text] [PDF]  

Outliers:Back

 Cartoon


Mol. Interv. 2006 6: 180. [Full Text] [PDF]  

To see an article, click its [Full Text] link. To review many summaries, check the boxes to the left of the titles you want, and click the 'Get All Checked Summary(s)' button. To see one summary at a time, click its [Summary] link.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.